1. Home
  2. IOVA vs RLJ Comparison

IOVA vs RLJ Comparison

Compare IOVA & RLJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • RLJ
  • Stock Information
  • Founded
  • IOVA 2007
  • RLJ 2011
  • Country
  • IOVA United States
  • RLJ United States
  • Employees
  • IOVA N/A
  • RLJ N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • RLJ Real Estate Investment Trusts
  • Sector
  • IOVA Health Care
  • RLJ Real Estate
  • Exchange
  • IOVA Nasdaq
  • RLJ Nasdaq
  • Market Cap
  • IOVA 975.1M
  • RLJ 1.1B
  • IPO Year
  • IOVA N/A
  • RLJ 2011
  • Fundamental
  • Price
  • IOVA $2.47
  • RLJ $7.66
  • Analyst Decision
  • IOVA Buy
  • RLJ Hold
  • Analyst Count
  • IOVA 12
  • RLJ 6
  • Target Price
  • IOVA $10.36
  • RLJ $9.21
  • AVG Volume (30 Days)
  • IOVA 20.9M
  • RLJ 1.9M
  • Earning Date
  • IOVA 11-06-2025
  • RLJ 11-05-2025
  • Dividend Yield
  • IOVA N/A
  • RLJ 7.85%
  • EPS Growth
  • IOVA N/A
  • RLJ N/A
  • EPS
  • IOVA N/A
  • RLJ 0.04
  • Revenue
  • IOVA $250,425,000.00
  • RLJ $1,351,163,000.00
  • Revenue This Year
  • IOVA $65.15
  • RLJ N/A
  • Revenue Next Year
  • IOVA $58.47
  • RLJ $2.49
  • P/E Ratio
  • IOVA N/A
  • RLJ $173.46
  • Revenue Growth
  • IOVA 175.62
  • RLJ N/A
  • 52 Week Low
  • IOVA $1.64
  • RLJ $6.16
  • 52 Week High
  • IOVA $9.70
  • RLJ $10.84
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 57.23
  • RLJ 64.35
  • Support Level
  • IOVA $2.09
  • RLJ $7.18
  • Resistance Level
  • IOVA $2.55
  • RLJ $7.67
  • Average True Range (ATR)
  • IOVA 0.24
  • RLJ 0.24
  • MACD
  • IOVA 0.01
  • RLJ 0.04
  • Stochastic Oscillator
  • IOVA 61.59
  • RLJ 88.29

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About RLJ RLJ Lodging Trust of Beneficial Interest $0.01 par value

RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.

Share on Social Networks: